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Effects of demethyichiortetracycline on cellular action of
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Mayo Foundation, Rochester, Minnesota
Effects of demethylchlortetracycline on cellular action of
antidiuretic hormone in vitro. Demethyichiortetracycline (DMC)
can induce a syndrome of nephrogenic diabetes insipidus in man
without affecting other renal functions. Because this pathologic
change might be due to interference with the cellular action of
antidiuretic hormone (ADH) on the distal nephron, we studied,
in vitro, the effect of DMC on some enzymes of the ADH-
dependent cyclic AMP (cAMP) system prepared from human
renal medulla. Increasing concentrations of DMC produced
increasing inhibition of adenylate cyclase basal activity and of
the activity stimulated by ADH or by sodium fluoride; at a
DMC concentration of 500 tg/nil the inhibition was about 50%.
The inhibition appears to be noncompetitive. The same doses of
DMC produced only slight inhibition of cAMP diesterase.
cAMP-dependent protein kinase contained in cytosol of renal
medulla also was inhibited by DMC. Therefore, DMC has the
potential to inhibit cAMP formation and the accumulation of
cAMP in the renal medulla in response to ADH and also to
inhibit cAMP-dependent phosphorylation of proteins in the
renal medulla. It is suggested that differential inhibition of these
enzymes might be the basis of the unresponsiveness to ADH
induced by this drug in vivo. Tetracycline and chlortetracycline
had the same effects as DMC in vitro. Additional factors would
probably determine why the effect is apparent in vivo only after
administration of DMC.
Effets de Ia demethylchlortetracycline sur l'action cellulaire de
l'hormone anti-diurétique fl Vitro. La demethylchlortetracycline(DMC) peut induire un syndrome de diabète insipide chez
l'homme sans atteindre d'autres fonctions rénales. Cette modifi-
cation pathologique peut étre liée a une interference avec l'action
ceilulaire de I'ADH sur Je néphron distal. Nous avons donc
étudié, in vitro, l'effet de DMC sur plusieurs enzymes du sys-
tème de l'AMP cyclique ADH dépendante préparées a partir de
médulaire humaine. Des concentrations croissantes de DMC
produisent une inhibition croissante de l'activité basale de
l'aeny1-cyclase et de l'activité stimulée par l'ADH ou le
fluorure de sodium. Pour des concentrations de 500 g/ml de
DMC, l'inhibition est a peu prés de 50%. L'inhibition parait non
competitive. Les mêmes concentrations de DMC ne produisent
qu'une inhibition minime de Ia cAMP diesterase. La protéine
kinase cAMP dépendante contenue dans Ic cytosol de Ia
médullaire rénale est inhibée, dIe aussi, par le DMC. Ainsi, le
DMC peut potentiellement inhiber Ia formation de cAMP et
son accumulation dans la mCdullaire rdnale en réponse a I'ADH.
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II peut aussi inhiber Ia phosphorylation, cAMP dépendante, des
protéines de la médullaire rénale. Ii est suggéré que l'inhibition
différentielle de ces enzymes puisse être Ia base de l'absence de
réponse a l'ADH induite par Ia drogue in vivo. La tetracycline
et la chlortetracycline ont les mêmes effets que le DMC in vitro.
Des facteurs supplémentaires expliquent, probablement, que
l'effet ne soit observe in VILO qu'aprôs Ia seule administration de
DMC.
Several reports in recent years have described a
syndrome of nephrogenic diabetes insipidus in patients
receiving demethylchlortetracycline (DMC) [1—4]. An
inability to concentrate urine properly in response to
antidiuretic hormone (ADH) could result from
inability to increase the water permeability of the
distal nephron or could be due to abolition of the
osmotic gradient between tubular urine and medullary
interstitial fluid. In DMC-induced nephrogenic dia-
betes insipidus, polyuria apparently is not due to the
inhibition of proximal sodium reabsorption or to in-
creased delivery of solutes from the proximal tubules
to the distal nephron [4—6]; also, other functions of the
proximal tubule are not impaired [4]. The toxic effect
of DMC is limited to the distal tubule, and it is con-
ceivable that the drug interferes with the action of
ADH at this site. It is generally accepted that the
action of ADH on the distal tubule in mammalian
kidney is mediated by cyclic AMP (cAMP) [7, 8].
To determine if DMC can interfere with ADH-
dependent cAMP metabolism in the renal medulla, we
studied the effect of DMC and some chemically re-
lated tetracyclines on adenylate cyclase, cAMP
phosphodiesterase, and cAMP-dependent protein
kinse in preparations from human renal medulla.
Methods
Renal medullary tissue was obtained from kidneys
that had been removed because of neoplastic lesions
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which did not involve the whole organ. The renal
tissue was immediately chilled in ice-cold 0.9% NaCI,
and all subsequent preparatory steps were performed
at 0° to 2°C. The medullary tissue was dissected free
from cortical and connective tissues. The enzyme
preparations were made immediately or the tissue was
frozen by immersion in liquid nitrogen and stored at
—80°C. Enzymes prepared from either fresh or frozen
tissue had identical properties. Enzyme extracts were
prepared from six different kidneys.
The tissue was minced with scissors and rinsed with
medium (0.25 M sucrose, 5 mrvi tris-HCI, 3 mM MgCI2,
and 1 mrvt EDTA [pH 7.4]) and then homogenized in a
glass-Teflon homogenizer in medium of the same
composition (tissue to medium ratio, about 1:5,
wt/vol). The homogenate was centrifuged at 600 x G
for ten minutes, and the supernate was set aside, The
sediment was resuspended in medium of the same
composition but without sucrose and centrifuged at
600 x G for ten minutes. This procedure was repeated
twice. The resulting washed 600xG sediment was
resuspended in the washing buffer, divided into small
portions, quickly frozen in dry ice, and stored at less
than — 80°C. The supernate from the first centri-
fugation was centrifuged at 120,000 x G for 90 minutes
in a preparative ultracentrifuge and the sediment was
discarded. This clear supernate was dialyzed over-
night against 300 vol of 10 mM tris-HC1 (pH 7.1). After
dialysis, the extract was divided into small portions,
frozen, and stored in separate tubes in the same way as
the 600 x G sediment.
Samples of particulate and soluble extracts were
dissolved in l% sodium dodecyl sulfate' for protein
determination by the method of Lowry et al [91.
Adenylate cyclase. The activity in the 600 x G sedi-
ment was assayed in an incubation mixture of the
following composition: [a-"P]ATP, 0.1 mM; MgCl2,
4mM; EDTA, 0.1 mM; bovine crystalline serum
albumin, 0.l%; cAMP, 0.5 mM; NaCI, 200 mM; urea,
200 mM; tn-sodium salt of creatine phosphate, 25 mM;
creatine kinase, 0.1 mg/mI; and tris-HCI, 40 m. The
incubation mixture had a pH of 7.4 and total osmolar-
ity was about 800 mOsm. Solutions of DMC and other
drugs were always freshly made prior to the assay
and adjusted to the pH of the incubation mixture by
addition of Tris. The incubation was stopped by
addition of a solution containing 25 mtvi cAMP,
25 mri AlP, 25 mri 5'-AMP, and 250 mM EDTA [10]
and heating in a boiling water bath for three minutes.
The particulate materials were sedimented by centri-
fugation in a centrifuge (Eppendorf 3200) (10,000 x G)
for 2.5 minutes and aliquots of the supernate were
1% sodium dodecyl sulfate did not interfere with the protein
determination.
analyzed by the method of McKenzie and Bar [10]. The
radioactivity of cAMP and substrate was counted in a
liquid scintillation spectrometer (Nuclear-Chicago
model 8760).
Protein kinase. This was assayed in the 120,000xG
supernate by incubating the enzyme extract with
[y — '2P]ATP in 200 l of incubation mixture of the
following composition: [y —'2P]ATP, 2.5 x 10 6 M
(106 cpm per tube); MgCI2, 10 mM; NaF, 10 mM;
theophylline, 8 mM; EDTA, 0.1 mM; KCI, 150 mM;
NaCI, 50 mM; urea, 200 mM; and sodium -glycero-
phosphate, 50 m. The pH of the incubation mixture
was 6.8. In some incubations, the protein contained
in the cytosol was used as a substrate ("endogenous
substrate"); in others 40 ig of mixed calf thymus
histones (Mann Laboratories) was added as artificial
substrate. The incubations were for ten minutes at
30°C and were stopped by addition of 0.2 ml of
solution containing 30% trichloroacetic acid (TCA),
1 mM AlP, and 0.1 mrvi P. The final mixture was
centrifuged and the precipitated proteins were dis-
solved in 0.1 ml of 1 M NaOH and then reprecipitated
by the addition of 2 ml of l0% TCA. This suspension
was thoroughly mixed, collected on 0.45 m filters
(HAWP Millipore), and washed five times with 10 ml of
5% TCA containing 0.1 mrvi KH,P04. The filters then
were dissolved in Bray's solution, and the radioactivity
was counted in the liquid scintillation spectrometer.
cAMP phosphodiesterase. The activity in the
120,000 x G supernate (cytosol) was measured by using
the principle described by Thompson and Appleman
[11]. The enzyme protein was incubated in 200 .d of a
medium of the following composition: 3H-labeled
cAMP, 5 x 10 M; MgCI2, 10 mM; KCI, 150 mM;
NaCI, 50 mM; urea 200 mM: and tris-HCI (pH 8.0),
80 m. The incubation was for 20 minutes at 37°C
and was stopped by heating in a boiling water bath
for three minutes. Then, 50 sl of 0.1% solution of
king cobra venom (Sigma Co.) was added and the
mixture was incubated again at 37°C for 15 minutes.
The second incubation was stopped by the addition of
1 ml of a slurry of AG 1 x 2, 200 to 400 mesh resin
(Bio-Rad Laboratories) in water (1:3), and the mix-
ture was centrifuged at 2,000 x G for five minutes.
Aliquots of the supernate were counted in the liquid
scintillation spectrometer. Neither DMC nor the
other tetracyclines influenced the binding of nucleo-
tides to the resin or the action of the 5'-nucleotidase
contained in the king cobra venom.
Results
The values of enzyme activities presented are means
of duplicate or triplicate assays.
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Table 1. Effect of tetracyclines on adenylate cyclase
Druga N Conc.,
i.g/ml
Basalb With AVP,"° 2 x 10-v M With NaF,b 10_a M
Mean % change Mean % change Mean % changeP P P
DMC 5 100 —22.8±8.0 <0.05 --18.9±4.7 <0.02 —17.6±3.7 <0.01
5 300
—30.0±12.1 NS --28.9±6.3 <0.02 —33.0±3.8 <0.01
5 500 —42.2±6.4 <0.005 --51.3±5.0 <0.00! —38.3±5.3 <0.005
TC 4 500 —35.7±5.3 <0.01 —41.1±6.4 <0.01 — —
CTC 4 500 —53.5±10.4 <0.02 —50.5±4.4 <0.005 — —
a DMC=demethyichiortetracycline; TC = tetracycline; CTC =chiortetracycline.b Control activities (pmoles/min/mg of protein± SaM): basal, 17.39 2.75; with AVP, 114.76± 20.50; with NaF, 177.91 12.17.
AVP= [8-arginine-vasopressin.
Increasing concentrations of DMC (100 to 500
g/ml) progressively inhibited basal adenylate cyclase
activity and the activity stimulated by subrnaximal
concentrations (2 x 10 M) of [8-arginine]-vasopres-
sin (AVP) or by 10 mist NaF. At 500 tg/ml, DMC
significantly inhibited all three activities. Tetracycline
(TC) and chlortetracycline (CTC) at 500 .tg/ml also
inhibited both basal and AVP-stimulated adenylate
cyclase (Table 1). The inhibition by DMC at 500 zg/ml
Table 2. Effect of tetracyclines on cAMP phosphodiesterase
Druga Conc., p.g/ml Mean % change SEM0 P
DMC 250
500
—5.0± 1.4
—16.5±1.7
<0.05
<0.001
TC 250
500
+0.3±1.7
—7.6±2.6
NS
<0.05
CTC 250
500
—4.3±2.9
—21.9±5.3
NS
<0.02
a. DMC =demethylchlortetracycline; TC = tetracycline; CTC=
chiortetracycline.b Control activity, 2.19±0.37 nmoles of cAMP/mm/mg of
protein; N= 5 for all means.
occurred at all levels of stimulation by ADH and,
therefore, appears to be noncompetitive (Fig. 1).
DMC also had a slight inhibitory effect on cAMP
AMP phosphodiesterase (Table 2). However, the inhi-
bition of AMP phosphodiesterase by 250 ig/ml DMC
was much less (in terms of percentage inhibition) than
the inhibition of AVP-stimulated adenylate cyclase by
100 g/m1 DMC (P<0.025) or 300 g/ml DMC
(P.<0.005). At concentrations of DMC of 500 g/ml,
the difference between the extent of inhibition of AVP-
stimulated adenylate cyclase (—5l.3%) and cAMP
phosphodiesterase (— 16.5%) was even more striking
(P<0.001). A similar relationship applies to the effect
of TC or CTC upon the two enzymes.
The specific activity of protein kinase in the cytosol
varied from preparation to preparation but activation
by cAMP (l06 M) caused about the same percentage
increase in enzyme activity. DMC inhibited protein
kinase activity in the presence and the absence of
cAMP (Table 3) and with endogenous substrate as
well as with added calf thymus histones. The marked
inhibitory effect of 500 tg/ml DMC on cAMP-
Table 3. Effect of tetracyclines on protein kinase activity
Substrate Druga N Basal With cAMP, 10_6 M
Mean % change5 P Mean °/ change P
Endogenous DMC
TC
CTC
4
4
4
—24.5±6.2
—13.0±3.9
—40.2±7.9
<0.05
<0.05
<0.02
—41.8±4.5
—21.5±5.1
—42.1±6.3
<0.005
<0.05
<0.01
Histones DMC
TC
CTC
4
3
4
—45.2±1.6
—36.0±4.0
—42.9±8.0
<0.001
<0.05
<0.02
—39.0±1.4
—28.0±4.2
—32.8±8.5
<0.001
<0.05
<0.05
All at 500 .ig/ml. DMC = demethylchlortetracycline; TC = tetracycline; CTC= chlortetracycline.
Control activities: endogenous, 0.99±0.36 pmoles of P/mm/mg of protein; with histones, 2.22± 1.02 pmoles
of P1/min/mg of protein.
Control activities: endogenous, 1.91 0.73 pmoles of P/mm/mg of protein; with histones, 4.43 1.50 pmoles
of P/min/mg of protein.
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stimulated protein kinase was (in terms of percentage With histones as substrate, DMC produced in-
inhibition) significantly different (P <0.005) from the hibition at all levels of stimulation by cAMP (Fig. 2),
mild decrease in the cAMP phosphodiesterase activity, indicating that the inhibition was not due to a decrease
stressing again differential effects of DMC on the of the apparent affinity of protein kinase for cAMP.
studied enzymes. Similar inhibition was observed with endogenous
substrate. TC and CTC had similar effects on the
cAMP-dependent protein kinase (Table 3).
Discussion
Recent reports indicate that the occurrence of
DMC-induced nephrogenic diabetes insipidus is
dependent on the total dose of drug given [5] and also
that the diluting function of the kidney is not im-
paired [5, 12]. Our analysis of renal function in three
patients who developed nephrogenic diabetes insipidus
while receiving DMC has shown that only distal tubu-
lar function is affected and the major impairment is in
the concentrating function of the distal nephron [4, 6]
with no major abnormality of renal handling of sod-
ium, phosphate, urate, potassium, glucose, or amino
acids and no major change in glomerular filtration
rate [4].
The fractional excretion of sodium did not change,
and the finding that the clearance of phosphorus re-
mained unchanged [4] also suggests that there was no
marked depression of proximal reabsorption of
sodium [13]. These data and the report by Singer and
Rotenberg [12] that the free-water clearance is not
changed in DMC-induced nephrogenic diabetes
insipidus indirectly indicate that the concentrating
defect is probably not due to decreased medullary
osmolality but that DMC interferes with the action of
ADH on the distal nephron.
Present results suggest that DMC does not affect the
affinity of the receptor for ADH. Sodium fluoride is
considered to stimulate hormone-responsive adenylate
cyclase at a site different from the hormonal receptor
[14] and, because DMC inhibited not only the ADH-
stimulated adenylate cyclase but also basal activity
and the fluoride-stimulated activity, we could infer
that the drug acts either on the catalytic unit itself or
on the step linking the ADH receptor with the catalytic
unit within the cell membrane.
It has been shown [15-171 that inhibition of cAMP
breakdown by cAMP phosphodiesterase can potentiate
the response to ADH in the target tissue. The effect of
______
DMC on this enzyme was tested in the present study
and slight inhibitory effects were found (Table 2).
The extent of inhibition of cAMP phosphodiesterase
(in terms of percentage decrease of activity), however,
was far less than the marked inhibition of ADH-
______
stimulated adenylate cyclase (Table 1) by the same or
similar concentrations of the drug. The major factor
I SEMI Control
DMC
500 g/ml
.
3
200
100
0 0 10° 106 l0 10 10
[8-argininel-vasopressin, M
Fig. 1. Stimulation of renal medullary adenylate cyclase by
increasing concentrations of vasopressin in absence
or in presence ( ) of demethyichiortetracycline (DMC) at
500 g/m1.
0 _
DMC
500 ig/ml
//__J_
0 10° 10-v 10 10-s
Cyclic AMP, M
Fig. 2. Stimulation of renal medullary protein kinase by in-
creasing concentrations of cAMP, with histones as substrate, in
absence ( ) and in presence (- - - - - - -) of demethyl-
chlortetracycline (DMC) at 500 tgiml.
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determining tissue level of cyclic AMP is the balance
between the rate of synthesis, through the action of
adenylate cyclase, and the rate of the breakdown by
cyclic AMP phosphodiesterase. We might infer from
our findings that the same concentration of DMC
would result in a net decrease of cylic AMP accumu-
lation in renal medulla through the prevailing in-
hibition of adenylate cyclase and therefore also in a
decreased response to ADH.
cAMP-dependent phosphorylation of proteins re-
cently has been implicated in the cellular action of
ADH on the distal nephron of mammalian kidney in
the steps subsequent to cAMP formation [8, 18].
Our finding that cAMP-dependent protein kinase is
inhibited by DMC points to the possibility that DMC
may exert its inhibitory effect on the cellular action of
ADH in the steps subsequent to cAMP formation.
The mechanisms by which DMC produces these
effects on adenylate cyclase, cAMP phosphodiesterase,
and cAMP-dependent protein kinase are not known.
All three enzymes are dependent on the presence of
magnesium for catalytic activity, and, therefore, one
possibility is the ability of tetracyclines to chelate
divalent ions [19]. However, this does not seem prob-
able because, in the incubation media for assays of
protein kinase and cAMP phosphodiesterase, the
magnesium concentration was 10-2 M, ten times higher
than the highest concentration of DMC (l0' M) used.
In the adenylate cyclase assay system used in this
study, decreasing the magnesium concentration from
4 m to 2 mri did not change the ADH-stimulated
adenylate cyclase activity in preparation from human
renal medulla (unpublished observations).
Even though TC and CTC had similar effects as
DMC in vitro, nephrogenic diabetes insipidus occurs
in vivo only after administration of DMC [4, 6, 20]. If
DMC induces the nephrogenic diabetes insipidus via
inhibition of adenylate cyclase and protein kinase,
why are the inhibitory effects of the other tetra-
cyclines not expressed in vivo? Several factors should
be considered in this regard. DMC has been shown to
be concentrated in the kidney at a level about five
times higher than the plasma concentration [21].
Moreover, those measurements were done in the whole
kidney, and it is possible that the DMC concentration
in the medullary portion is even higher than in the
whole homogenized organ. The nature of the inhib-
itory effect of DMC on adenylate cyclase suggests
that the drug acts on sites on the interior surface or
within the membrane (effect on basal activity,
fluoride-stimulated activity). Therefore, penetration of
the drug into the cell could be an important factor in
the action of DMC on adenylate cyclase as well as on
the two other enzymes in vivo. The t-- of disappearance
of DMC from plasma is much longer than that of
tetracycline or other derivatives, and the accumulated
urinary excretion of DMC is less than for these other
tetracycline drugs [221. This difference in the kinetics
of DMC in the whole organism might conceivably be
due to, or result in, a relatively higher accumulation of
DMC in the cells.
Moreover, our recent clinical study [4] suggests that
a small decrease in ADH-dependent concentrating
ability also occurs after administration of tetracycline,
opening the possibility that the difference between the
actions of DMC and of other tetracyclines observed
in vivo is only relative.
The hypothesis that DMC produces nephrogenic
diabetes insipidus in man through inhibition of renal
medullary adenylate cyclase, and possibly also protein
kinase, is supported by findings reported recently by
Singer and Rotenberg [12]. In their study, DMC
inhibited the hydroosmotic response of toad bladder
to ADH (apparently on the serosal site) in the same
range of concentrations (0.1—0.5 mg/ml) which in-
hibited adenylate cyclase in our cell-free system, and
DMC inhibited, to lesser degree, the response to exog-
enous cAMP. These results obtained on another
experimental model also suggest that DMC interferes
with cellular action of ADH by inhibition of ADH-
dependent cAMP formation as well as in steps sub-
sequent to cAMP generation. Also, analysis of experi-
mental models of nephrogenic diabetes insipidus
(hereditary [23] or induced by drugs such as lithium
[24, 25] or BAX 439 [26]) shows that ADH resistance
in vivo in all instances was associated with a decrease
in ADH-dependent cAMP formation in the renal
medulla.
We conclude that in vitro DMC and other tetra-
cyclines have the potential to inhibit ADH-dependent
adenylate cyclase and protein kinase and we suggest
that inhibition of these enzymes might be the patho-
genic basis for the ADH resistance found in DMC-
induced diabetes insipidus. This evidence is still
inferential although it is in agreement with findings
from other systems. Additional factors, such as
differential penetration of tetracyclines into renal
distal tubular cells, could determine why only DMC
has ADH-inhibiting effects in vivo.
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